Édina Caroline Ternus Ribeiro, Marla Darlene Machado Vale, João Guilherme Sparrenberger Dos Santos, Ingrid da Silveira Knobloch, Ingrid Dalira Schweigert Perry, Gabriela Corrêa Souza, Nadine Clausell
PhA demonstrated accuracy in identifying frailty and predicted prognosis in individuals with HF. Thus, the assessment of PhA in this population may represent a useful complementary marker in the identification of frailty and assessment of prognosis in clinical practice.
BACKGROUND: Although frailty often coexists with heart failure (HF) and can have a significant impact on prognosis, its assessment in clinical practice is challenging. Therefore, it is pertinent to study new objective methods that can help identify frailty.
OBJECTIVE: To evaluate the diagnostic and prognostic implications of phase angle (PhA) as a marker of frailty and prognosis in HF.
METHODS: Prospective cohort study, with a sample composed of adults HF outpatients. Frailty was assessed using the Fried Frailty Phenotype. To obtain PhA, bioelectrical impedance analysis (Tetrapolar Biodynamics©, model 450) was used, according to the standard protocol. The prognosis (all-cause and cardiovascular (CV) mortality, hospitalization for all causes, CV and HF, and composite endpoint (CV mortality or HF hospitalization)) was also assessed.
RESULTS: A total of 340 individuals were included, the majority of whom were male (67.6%), with a mean age of 60.39±12.69 years, with a mean left ventricular ejection fraction of 33.79±12.49. The PhA demonstrated accuracy in identifying frailty (AUC=0.714 (0.647-0.781) p=0.001). From the coordinates of the ROC curve, the cutoff point of 5.8° was identified, which demonstrated an independent association with frailty (Prevalence Ratio=1.84, p=0.001), hospitalization for HF (Hazard Ratio (HR)=2.68, p=0.001 and composite endpoint (HR=2.18, p=0.005). When analyzed continuously, PhA was associated with all outcomes, with risk decreasing for 1° increase (ranging from 22.8-45.2%).
CONCLUSION: PhA demonstrated accuracy in identifying frailty and predicted prognosis in individuals with HF. Thus, the assessment of PhA in this population may represent a useful complementary marker in the identification of frailty and assessment of prognosis in clinical practice.